An integrin-targeted, pan-isoform, phosphoinositide-3 kinase inhibitor, SF1126, has activity against multiple myeloma in vivo

PURPOSE: Multiple reports point to an important role for the phosphoinositide-3 kinase (PI3K) and AKT signaling pathways in tumor survival and chemoresistance in multiple myeloma (MM). The goals of our study were: (1) to generate the preclinical results necessary to justify a Phase I clinical trial...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: De, Pradip, Dey, Nandini, Terakedis, Breanne, Bersagel, Leif, Li, Zhi Hua, Mahadevan, Daruka, Garlich, Joseph R., Trudel, Suzanne, Makale, Milan T., Durden, Donald L.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2013
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3832139/
https://ncbi.nlm.nih.gov/pubmed/23355037
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-013-2078-0
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller